Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 29 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

7%

2 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

22Total
Not Applicable (14)
P 1 (3)
P 2 (3)
P 3 (2)

Trial Status

Unknown13
Recruiting5
Completed4
Not Yet Recruiting4
Active Not Recruiting2
Withdrawn1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 4 completed trials

Clinical Trials (29)

Showing 20 of 20 trials
NCT06825091Phase 3Recruiting

Is Adaptive SBRT for Prostate vs Image-guided Radiotherapy a True Evolution (ASPIRE)

NCT07289646Phase 3Not Yet RecruitingPrimary

Functional Lung Avoidance Planning Guided by Lung Perfusion PET/CT Versus Anatomical Planning for Lung Stereotactic Body Radiotherapy

NCT06822491Active Not Recruiting

Early Magnetic Resonance Imaging Response of the Dominant Intraprostatic Lesion After Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer and Correlation With Prostate Specific Antigen Response

NCT07285538Not ApplicableNot Yet Recruiting

Stereotactic Body RadioTherapy With Continuous Tracking for Primary and Secondary Renal Cancer

NCT06542159Phase 2Recruiting

Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases

NCT06760221Not ApplicableRecruiting

Safety and Efficacy of Preoperative SBRT and Radical Surgery for Soft Tissue Sarcoma of Extremities

NCT06722885Withdrawn

Stereotactic Body Radiotherapy for Lung Lesions With Markerless Tracking (MLT) on the VERO® SBRT System

NCT06595108Not ApplicableRecruiting

Atezolizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma

NCT06408753Completed

Plasma Biomarker in Predicting Response and Toxicity in HCC Patients Treated With Checkpoint Inhibitors With or Without SBRT

NCT05615142Phase 1Recruiting

Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.

NCT06195254CompletedPrimary

Stereotactic Body Radiotherapy Combined With PD-1 Blockers for Locally Advanced or Locally Recurrent Pancreatic Cancer

NCT06167876Not ApplicableUnknown

Safety and Efficacy of Stereotactic Body Radiotherapy in the Treatment of Hypertrophic Obstructive Cardiomyopathy

NCT05101824Not ApplicableActive Not Recruiting

Bony M - Stereotactic Ablative Radiotherapy (SABR) of Bony Metastases in Patients With Oligometastatic Disease

NCT05919641Unknown

LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT

NCT05915481Phase 1Unknown

Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors

NCT05802654Not ApplicableNot Yet Recruiting

Single Ultra-high Dose Stereotactic Body Radiation Therapy for Early Lung Cancer

NCT05802641Unknown

Stereotactic Radiotherapy With Different Fractionation Modes for the Early Lung Cancer

NCT05286320Phase 1Not Yet Recruiting

Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.

NCT05598060Not ApplicableUnknown

Preoperative Stereotactic Body Radiotherapy (SBRT) Followed by Hepatectomy for Centrally Located Hepatocellular Carcinoma: a Prospective, Single-center, Phase I Study

NCT05430737Not ApplicableUnknown

A Phase II Clinical Study of Stereotactic Radiation Therapy in Patients With High-risk Prostate Cancer

Scroll to load more

Research Network

Activity Timeline